028300.KQ
HLB Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 32,800.00
−1.65%Year over year
Reported trailing growth
- Revenue
- +29.0%
- EBITDA
- -8.9%
- EBIT
- +4.0%
- EPS
- -48.0%
- Free cash flow
- +19.0%
- Operating cash flow
- +1.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -22.4%
- EBITDA
- -1.8%
- EBIT
- +16.2%
- Net income
- —
- EPS
- —
- Free cash flow
- +22.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026